Stock 6996 ANTENGENE CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Antengene Corporation Limited

Equities

6996

KYG039571008

Delayed Hong Kong S.E.
Other stock markets
 04:08:11 2024-05-08 EDT 		5-day change 1st Jan Change
1.06 HKD -0.93% Intraday chart for Antengene Corporation Limited +3.92% -47.00%
05-02 Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop MT
04-29 Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
AQ
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress across First-in-Class, Best-in-Class Pipeline
AQ
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
AQ
Antengene Announces Inclusion of XPOVIO in 2023 China's National Reimbursement Drug List
AQ
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
PR
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
AQ
Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and or Refractory Multiple Myeloma
AQ
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
PR
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
AQ
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
PR
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
PR
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
PR
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting
PR
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
AQ
Antengene Voluntarily Lowers the Price of XPOVIO in China to Allow More Patients with Multiple Myeloma to Benefit from the Drug
AQ
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline
AQ
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline
PR
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China
PR
Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States
PR
Antengene Announces XPOVIO Regulatory Approval in Hong Kong for the Treatment of Relapsed and or Refractory Multiple Myeloma
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6996 Stock
  4. News Antengene Corporation Limited
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW